Abstract
Junction-mediating and regulatory protein (JMY) is a novel p53 cofactor that regulates p53 activity during stress. JMY interacts with p300/CBP, which are ubiquitous transcriptional co-activators that interact with a variety of sequence-specific transcription factors, including hypoxia-inducible factor-1α (HIF-1α). In addition, JMY is an actin-nucleating protein, which, through its WH2 domains, stimulates cell motility. In this study, we show that JMY is upregulated during hypoxia in a HIF-1α-dependent manner. The JMY gene contains HIF-responsive elements in its promoter region and HIF-1α is recruited to its promoter during hypoxia. HIF-1α drives transcription of JMY, which accounts for its induction under hypoxia. Moreover, the enhanced cell motility and invasion that occurs during hypoxia requires JMY, as depleting JMY under hypoxic conditions causes decreased cell motility. Our results establish the interplay between JMY and HIF-1α as a new mechanism that controls cell motility under hypoxic stress.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Biswas S, Troy H, Leek R, Chung YL, Li JL, Raval RR et al. (2010). Effects of HIF-1alpha and HIF-2alpha on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts. J Oncol 2010: 757908.
Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, La Thangue NB . (2001). Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol 3: 667–674.
Coutts AS, Boulahbel H, Graham A, La Thangue NB . (2007). Mdm2 targets the p53 transcription cofactor JMY for degradation. EMBO Rep 8: 84–90.
Coutts AS, Weston L, La Thangue NB . (2009). A transcription co-factor integrates cell adhesion and motility with the p53 response. Proc Natl Acad Sci USA 106: 19872–19877.
Dang DT, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F et al. (2006). Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res 66: 1684–1936.
Demonacos C, Krstic-Demonacos M, La Thangue NB . (2001). A TPR motif cofactor contributes to p300 activity in the p53 response. Mol Cell 8: 71–84.
Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT et al. (2006). Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440: 1222–1226.
Ferrara N, Hillan KJ, Novotny W . (2005). Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333: 328–335.
Harris AL . (2002). Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38–47.
Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, Kessler B et al. (2008). Arginine methylation regulates the p53 response. Nat Cell Biol 10: 1431–1439.
Kaelin Jr WG, Ratcliffe PJ . (2008). Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393–402.
Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek JH et al. (2006). Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 66: 2725–2731.
Lee K, Lee JH, Boovanahalli SK, Jin Y, Lee M, Jin X et al. (2007). (Aryloxyacetylamino)benzoic acid analogues: a new class of hypoxia-inducible factor-1 inhibitors. J Med Chem 50: 1675–1684.
Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M et al. (2007). Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 67: 11244–11253.
Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G . (2006). Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13: 927–934.
Rankin EB, Giaccia AJ . (2008). The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15: 678–685.
Rapisarda A, Shoemaker RH, Melillo G . (2009). Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads. Cell Cycle 8: 4040–4043.
Semenza GL . (2010). Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625–634.
Shikama N, Lee CW, France S, Delavaine L, Lyon J, Krstic-Demonacos M et al. (1999). A novel cofactor for p300 that regulates the p53 response. Mol Cell 4: 365–376.
Spinella F, Rosano L, Di Castro V, Decandia S, Nicotra MR, Natali PG et al. (2007). Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. Cancer Res 67: 1725–1734.
Sullivan R, Graham CH . (2007). Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 26: 319–331.
Wang GL, Jiang BH, Rue EA, Semenza GL . (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510–5514.
Wang GL, Semenza GL . (1993). Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82: 3610–3615.
Zalmas LP, Zhao X, Graham AL, Fisher R, Reilly C, Coutts AS et al. (2008). DNA-damage response control of E2F7 and E2F8. EMBO Rep 9: 252–259.
Zuchero JB, Coutts AS, Quinlan ME, La Thangue NB, Mullins RD . (2009). p53-cofactor JMY is a multifunctional actin nucleation factor. Nat Cell Biol 11: 451–459.
Acknowledgements
We thank the MRC, CRUK, LRF and AICR for support. ASC and LW are funded by MRC and CRUK (grant # C300/6731). IMP and EMH are funded by CRUK (grant # C6415/A9321). We also thank Long Dang, Peter Ratcliffe and Shoumo Bhattacharya for providing invaluable reagents.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Coutts, A., Pires, I., Weston, L. et al. Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1α. Oncogene 30, 4835–4842 (2011). https://doi.org/10.1038/onc.2011.188
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.188
Keywords
This article is cited by
-
p53-dependent DNA repair during the DNA damage response requires actin nucleation by JMY
Cell Death & Differentiation (2023)
-
Dysregulation of iron homeostasis and methamphetamine reward behaviors in Clk1-deficient mice
Acta Pharmacologica Sinica (2022)
-
WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer
British Journal of Cancer (2018)
-
Regulation of actin nucleation and autophagosome formation
Cellular and Molecular Life Sciences (2016)
-
Actin nucleation by WH2 domains at the autophagosome
Nature Communications (2015)